<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:ifp="http://www.ifactory.com/press" ifp-element-xpath="/*[local-name() = 'urlset' and namespace-uri() = 'http://www.sitemaps.org/schemas/sitemap/0.9']"><ifp:contentType>ARTICLE</ifp:contentType><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-pxxiv.xml</sm:loc><ifp:title>NCCN News</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-pxxiv.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>NCCN News</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1032.xml</sm:loc><ifp:title>Letter to the Editor: Significance of Clonal Hematopoiesis of Indeterminate Potential</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1032.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Letter to the Editor: Significance of Clonal Hematopoiesis of Indeterminate Potential</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1031.xml</sm:loc><ifp:title>Getting What You Pay For: Finding Value in Cancer Care</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1031.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Getting What You Pay For: Finding Value in Cancer Care</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-pxxxix.xml</sm:loc><ifp:title>Oncology Research Program</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-pxxxix.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Oncology Research Program</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1041.xml</sm:loc><ifp:title>NCCN Guidelines Insights: Bladder Cancer, Version 5.2018</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1041.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>NCCN Guidelines Insights: Bladder Cancer, Version 5.2018</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1075.xml</sm:loc><ifp:title>Benchmarking Cancer Centers: From Care Pathways to Integrated Practice Units</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1075.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Benchmarking Cancer Centers: From Care Pathways to Integrated Practice Units</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1055.xml</sm:loc><ifp:title>Use of Inpatient Palliative Care Services in Patients With Advanced Cancer Receiving Critical Care Therapies</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1055.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Use of Inpatient Palliative Care Services in Patients With Advanced Cancer Receiving Critical Care Therapies</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1035.xml</sm:loc><ifp:title>Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1035.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1065.xml</sm:loc><ifp:title>Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1065.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1092.xml</sm:loc><ifp:title>Chimeric Antigen Receptor T-Cell Therapy</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1092.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Chimeric Antigen Receptor T-Cell Therapy</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1084.xml</sm:loc><ifp:title>Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1084.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1157.xml</sm:loc><ifp:title>Being Critical of Critical Care Given to People With Metastatic Cancer: Get Palliative Care Involved</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1157.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Being Critical of Critical Care Given to People With Metastatic Cancer: Get Palliative Care Involved</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1150.xml</sm:loc><ifp:title>Resurrection of PARP Inhibitors in Breast Cancer</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1150.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Resurrection of PARP Inhibitors in Breast Cancer</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1108.xml</sm:loc><ifp:title>Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1108.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1137.xml</sm:loc><ifp:title>Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/16/9/article-p1137.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer</ifp:title></sm:url></urlset>
